medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2007, Number 4

<< Back Next >>

Ann Hepatol 2007; 6 (4)

Combined therapy with danazol, pegilated interferon, and ribavirin improves thrombocytopenia and liver injury in rats with fibrosis

Cabrera ÁG, Madrid-Marina V, Jimenez-Mendez R, Leon BA, Bahena RM, Cortez-Gomez R, Reyes EJ, Rodríguez-Fragoso L

Language: English
References: 60
Page: 233-241
PDF size: 235.91 Kb.


Text Extraction

The aim of this study was to investigate the effects of combinations of pegilated–interferon (PEG–IFN), ribavirin, and danazol on thrombocytopenia and liver injury in rats with fibrosis. Male adult Wistar rats were treated with either mineral oil, danazol (0.83 mg/kg per day), PEG–interferon α-2a (PEG–IFN, 0.3 µg/week) + ribavirin (12 mg/kg per day), PEG–IFN + ribavirin + danazol, CCl4 (4 g/kg for eight weeks), CCl4 + PEG–IFN + ribavirin, or CCl4 + PEG–IFN + ribavirin + danazol. The following assays were conducted: hematology, clinical chemistry, liver function, liver fibrosis, lymphocyte cytokine mRNA expression, and bone-marrow DNA content. Platelet counts were low in sham-treated animals and animals treated with PEG–IFN + ribavirin (30% and 25% respectively; P ‹ 0.05). PEG–IFN + ribavirin + danazol reduced platelet counts of fibrotic animals by only 9% (P ‹ 0.05). PEG–IFN + ribavirin reduced hepatic collagen content by 50%, whereas danazol + PEG–IFN + ribavirin reduced hepatic collagen content by 60% (P ‹ 0.05). PEG–IFN + ribavirin reduced the total bilirubin concentration by 27%, alanine amino transferase (ALT) activity by 75% and γ-glutamyl transpeptidase (γ-GTP) activity by 74% (P ‹ 0.05). In contrast, danazol + PEG–IFN + ribavirin reduced total bilirubin levels by 61%, alkaline phosphatase activity by 45%, ALT activity by 76%, and γ-GTP activity by 74% (P ‹ 0.05). The only treatment that increased interleukin 10 (IL-10) mRNA in fibrotic rats was PEG–IFN + ribavirin. However, danazol + PEG–IFN + ribavirin reduced the expression of IL-6, IL-10, tumor necrosis factor α and transforming growth factor β. Bone-marrow DNA content was not altered by any treatment. In conclusion, PEG–IFN + ribavirin + danazol could be a new therapeutic option for patients with liver injury, fibrosis, and thrombocytopenia.


REFERENCES

  1. Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006; 24: 661-72.

  2. Wong T, Lee SS. Hepatitis C: a review for primary care physicians. CMAJ 2006; 174: 649-59.

  3. Rockey DC. The cell and molecular biology of hepatic fibrogenesis. Clinical and therapeutic implications. Clin Liver Dis 2000; 4: 319-55.

  4. Marra F. Chemokines in liver inflammation and fibrosis. Front Biosci 2002; 7: 1899-1914.

  5. Tilg H, Kaser A, Moschen AR. How to modulate inflammatory cytokines in liver diseases. Liver Int 2006; 26: 1029-39.

  6. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti Yamamoto, A, et al. Extrahepatic manifestations associated with hepatitis C virus infection. Medicine 2000; 79: 47-56.

  7. Séne D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 2004; 19: 357-80.

  8. Wang C-S, Yao W-J, Wang S-T, Chang T-T, Chou P. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis 2004; 39: 790-6.

  9. Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Hematol 2005; 129: 818-24.

  10. Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y, Kuwana M. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37: 1267-76.

  11. Vyzantiadis T, Theodoridou S, Giouleme O, Evgenidis N, Vyzantiadis A, Garipidou V. Serum thrombopoietin levels in thrombocytopenic patients with liver cirrhosis. Haematologica 2002; 87: 890-1.

  12. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.

  13. Anatol P, Robert F, Danuta P. Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C. World J Gastroenterol 2005; 11: 1854-8.

  14. Sporea I, Popescu A, ªirli R, Golea O, Totolici C, Dãnilã M, Vernic C. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006; 12: 4191-94.

  15. Garcia-Suarez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, varez-Mon M. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant a2b-interferon therapy. Br J Haematol 2000; 110: 90-103.

  16. Dimitroulopoulos D, Dourakis SP, Xinopoulos D, Tsamakidis K, Paraskevas E. Immune thrombocytopenic purpura in a patient treated with interferon alfacon-1. J Viral Hepatitis 2004; 11: 477-8.

  17. Sevastianos VA, Deutsch M, Dourakis SP, Manesis EK. Pegylated interferon-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C. Am J Gastroenterol 2003; 98: 706-7.

  18. Mylvaganam R, Ahn Y, Harrington W, Kim CI. Immune modulation by danazol in autoimmune thrombocytopenia. Clin Immunol Immunopathol 1987; 42: 281-6.

  19. Mylvaganam R, Ahn Y, Garcia R, Kim C, Harrington W. Very low-dose danazol in idiopathic thrombocytopenic purpura and its role as an immune modulator. Am J Med Sci 1989; 298: 215-20.

  20. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, Sanchez-Andrade A, Gonzalez-Gay MA. Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. Br J Rheumatol 1997; 36: 1095-9.

  21. Nakhoul IN, Kozuch P, Varma M. Management of adult idiopathic thrombocytopenic purpura. Clin Adv Hematol Oncol 2006; 4: 136-153.

  22. Stasi R, Pravan D. Management of thrombocytopenic purpura in adults. Mayo Clin Proc 2004; 79: 504-22.

  23. Cines DB, McKenzie SE, Siegel DL. Mechanisms of action of therapeutics in idiopathic thrombocytopenic purpura. J Pediatric Hematol Oncol 2003; 25: S52-S56.

  24. Committee on Care and Use of Laboratory Animals of the Institute for Laboratory Animal Resources, Commission on Life Sciences, National Research Council: Guide for the Care and Use of Laboratory Animals. Publication 86-23, revised. National Academy of Sciences, Washington DC, EEUU.

  25. Rojkind M, Gonzalez E. An improved method for determining specific radioactivities of proline-14C and hydroxyproline-14C in collagen and noncollagenous protein. Anal Biochem 1974; 57: 1-7 [PMID: 4817495].

  26. Chomozynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem 1987; 162: 157-63.

  27. Derynck R, Jarrett J, Chen E, Goeddel D. The murine transforming growth factor-beta precursor. J Biol Chem 1986; 261: 4377-9.

  28. Sun J, Wang XD, Liu H, Xu JG. Ketamine suppresses intestinal NF-kappa B activation and proinflammatory cytokine in endotoxic rat. World J Gastroenterol 2004; 10: 1028-31.

  29. Pietsch K, Ehlers S, Jacobs E. Cytokine gene expression in the lungs of BALB/c mice during primary and secondary intranasal infection with Mycoplasma pneumoniae. Microbiology 1994; 140: 2043-8.

  30. Méndez-Herrera MC, Támez L, Candido A, Reyes-Esparza J, Pedernera E. Follicle stimulating hormone increases somatic and germ cell number in the ovary during chick embryo development. Gen Comp Endocrinol 1998; 111: 207-15.

  31. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, et al. GERMED cyt04 group. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: Longitudinal validation in a randomized trial. J Viral Hepat 2002; 9: 128-33.

  32. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.

  33. Shimotohno K. Hepatitis C virus and its pathogenesis. Semin Cancer Biol 2000; 10: 233-40.

  34. Paleka NA, Harrison SA. Extrahepatic manifestations of hepatitis C. South Med J 2005; 98: 1019-23.

  35. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006; 23: 1055-1065.

  36. Cines DB, Lanchette VS. Immune thrombocytopenia purpura. N Engl J Med 2002; 346: 995-1008.

  37. Demirturk N, Cevik F, Demirdal T, Aykin N, Aslan V. Autoimmune thrombocytopenia induced by PEG–IFN-alpha plus ribavirin in hepatitis C. Platelets 2006; 17: 340-3.

  38. Maloisel F, Andres E, Zimmer J, Noel E, Zamfir A, Koumarianou, A, Dufour P. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 2004; 116: 590-4.

  39. Lancia A, Colella F, Nicolella U, Grandioso P, Di Virgilio D. Hepatic damage after danazol treatment. Ital J Gastroenterol 1991; 23: 15-16.

  40. Yaginuma T, Okamura T, Takeuchi T, Nishii O, Fujimori R. Preventive effect of traditional herbal medicine, shosaiko-to, on danazol-induced hepatic damage. Int J Gynaecol Obstet 1989; 29: 337-4.

  41. Silva MO, Reddy KR, McDonald T, Jeffers LJ, Schiff ER. Danazol-induced cholestasis. Am J Gastroenterol 1989; 84: 426-8.

  42. Alvaro D, Piat C, Francia C, Franchitto A, Furfaro S, Valente C, Capocaccia L, et al. Ultrastructural features of danazol-induced cholestasis: a case study. Ultrastruct Pathol 1996; 20: 491-5.

  43. Estrada Rodríguez JL, Jorquera Plaza, Gozalo Reques F, Álvarez Puebla MJ. Hepatitis por danazol en paciente con déficit funcional de C1 inhibidor. Anales de Medicina Interna 2001; 18: 605-6.

  44. Confavreux C, Se‘ve P, Broussolle C. Danazol-induced hepatocellular carcinoma. Q J Med 2003; 96: 315-8.

  45. Alvaro D, Piat C, Francia C, Franchitto A, Furfaro S, Valente C, Capocaccia L, et al. Ultrastructural features of danazol-induced cholestasis: a case study. Ultrastruct Pathol 1996; 20: 491-5.

  46. Bartley J, Loddenkemper C, Lange J, Mechsner S, Radke C, Neuhaus P, Ebert AD. Hepatocellular adenoma and focal nodular hyperplasia after long-term use of danazol for endometriosis: a case report. Arch Gynecol Obstet 2004; 269: 290-3.

  47. Hayashi T, Takahashi T, Minami T, Akaike J, Kasahara K, Adachi M, Hinoda Y, et al. Fatal acute hepatic failure induced by danazol in a patient with endometriosis and aplastic anemia. J Gastroenterol 2001; 36: 783-6.

  48. Cicardi M, Bergamaschini L, Tucci A, Agostoni A, Tornaghi G, Coggi G, Colombi R, et al. Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J Allergy Clin Immunol 1983; 72: 294-8.

  49. Monnier N, Ponard D, Duponchel C, Csopaki F, Bouillet L, Tosi M, Lunardi J, et al. Characterisation of a new C1 inhibitor mutant in a patient with hepatocellular carcinoma. Mol Immunol 2006; 43: 2161-8.

  50. Friedman SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 98-105.

  51. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005; 42: S22-S36.

  52. Castet V, Fournier C, Soulier A, Brillet R, Coste J, Larrey D, Dhumeaux D. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol 2002; 76: 8189-99.

  53. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.

  54. Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N. Progesterone and progestational compounds attenuate tumor necrosis factor alpha–induced interleukin-8 production via nuclear factor kappaB inactivation in endometriotic stromal cells. Fertil Steril 2005; 83: 1530-5.

  55. Neuman MG, Benhamou J, Malkiewicz IM, Akremi R, Shear NH, Asselah T, et al. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochem 2001; 34: 173-82.

  56. Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Machowska L, S³uzewski1 W. Interleukin 6 and 12, alanine aminotransferase activity, and HCV viral load in children with chronic hepatitis C treated with interferon and ribavirin. Inflammation 2004; 28: 320-4.

  57. Marýn-Serrano E, Rodrýiguez-Ramos C, Diaz F, Martín-Herrera L, Giron-Gonzalez JA. Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. J Viral Hepat 2006; 13: 230-34.

  58. Vigano P, Di Blasio AM, Busacca M, Sabbadini MG, Vignali M. Danazol suppresses both spontaneous and activated human lymphocyte-mediated cytotoxicity. Am J Reprod Immunol 1992; 28: 38-42.

  59. Matalliotakis I, Neonaki M, Zolindaki A, Hassan E, Georgoulias V, Koumantakis E. Changes in immunologic variables (TNF-a, sCD8 and sCD4) during danazol treatment in patients with endometriosis. Int J Fertil Womens Med 1997; 42: 211-4.

  60. Liu Y, Luo L, Zhao H. In vitro effect of danazol on cytokine production of macrophages in peritoneal fluid of infertile patients with endometriosis and its relationship with cytosolic free calcium concentration. Zhonghua Fu Chan Ke Za Zhi 2000; 35: 479-81.




2020     |     www.medigraphic.com